Rezultati pretraživanja
  1. prije 27 minuta

    Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - 

  2. Odgovor korisnicima

    Hodge-podge spin out by includes marketing org for drugs licensed from Samsung Bioepis. Would make sense to do another spin out creating pure co and then buy with better marketing org. Eliminate duplicate R&D and fill each other’s gaps

  3. . of discusses the emergence of in oncology and how he anticipates they will change the paradigm

  4. prije 3 sata
  5. prije 7 sati

    BREAKING: ⁦⁩ announces spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran.

  6. prije 8 sati

    How much does your state save? In 2018, generic prescription medicines saved $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved:

  7. prije 8 sati

    Lack of penetration of infliximab : Is this news to anyone?

  8. prije 8 sati
    Odgovor korisnicima

    just did a spin out of hodge-podge product lines including licensed from Samsung Bioepis. Would make sense for to do another spinout of then do a M&E with with better marketing org. Eliminate duplicate R&D. Also each fills gaps in other

  9. prije 8 sati
    Odgovor korisniku/ci

    check out my latest post on spin out of hodge-podge product lines including licensed from Samsung Bioepis. Would make sense for to do another spinout of then do a M&E with with better marketing org. Eliminate duplicate R&D.

  10. prije 8 sati

    -- new hodge-podge spin out includes marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure co and buy with better marketing org. Eliminate duplicate R&D (even I can make a bull case for )

  11. prije 9 sati

    has a set back on Lucentis biosimilar: BLA submission withdrawn after FDA concerns over manufacturing.

  12. Enter US Market, Poised to Impact Treatment

  13. Interesting...business and property concerns but I wonder how they will address bioequivalence challenges....insights welcome as I'm definitely not well-versed!

  14. prije 11 sati
  15. prije 11 sati

    Check out my recent article in Pharmaceutical Technology on the potential impact of in 2020.

  16. prije 11 sati

    . to spin-off & into unnamed company to achieve $1.5B in operating efficiencies by 2024 NewCo also to snag legacy brands in , , & some markets

  17. prije 12 sati

    The FTC and the New York Attorney General have sued Vyera Pharmaceuticals and two of its executives for antitrust law violations. Read about the challenges of bringing biosimilars to market by clicking here:

  18. Dr. Sarah Yim, Director of the Office of 's OTBB, hopes to see comparable robustness of the U.S. market to the European market in 10 years

  19. prije 12 sati
    Odgovor korisniku/ci

    are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here.

  20. Looking for information about and ? Take a peek at our sheet, and learn why we advocate for patient-doctor choice 👨‍⚕️🏥👩‍⚕️.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.